Loading...

FLGT FULGENT GENETICS INC US FDA Inspections 8-K Filing

FLGN

FLGT

FULGENT GENETICS INC

(FLGT)

2025 8-K

Asset Acquisition Completed

Quarterly Results

Acquisition Announcement

Financial Results Report

Clinical Trial Update

Financial Statements

Financial Results

Financial Results

Earnings Reports

Earnings Reports

Earnings Reports

Earnings Reports

Earnings Reports

Annual Meeting Approval

Earnings Reports

Earnings Reports

Lease Extension

Appointment of Director

External Links:

On October 20, 2025, Fulgent Genetics, Inc. announced preliminary clinical data from a Phase 2 trial of FID-007 combined with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma.

AI Assistant

FULGENT GENETICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.